Compounded tirzepatide injection information for a clinician-guided weight-management discussion.
Compounded · Not FDA-approvedCompounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Prepared by a state-licensed compounding pharmacy operating under Section 503A. Appropriateness and lawful availability require individual clinician and licensed-pharmacy review.
Subcutaneous injection
Dual GIP / GLP-1 receptor agonist
Compounded by a licensed 503A pharmacy
Weight-management treatment may be considered for eligible adults after a licensed clinician reviews medical need, alternatives, contraindications, and whether compounding is appropriate and lawfully available. This listing is not an eligibility determination or prescription.
Tirzepatide activates GIP and GLP-1 receptors, influencing appetite, gastric emptying, and glucose regulation. These mechanisms do not establish a particular outcome for a compounded formulation.
Compounded tirzepatide is prescribed only when a licensed provider determines it is clinically appropriate. Compounded medications are not FDA-approved.
Published studies provide ingredient-level context in specific populations. They are not clinical trials of this compounded medication and do not establish its potency, dosing, safety, efficacy, or outcomes. Individual results vary.
A treatment listing does not determine eligibility or guarantee a prescription.
Medical history, weight trajectory, treatment goals, current medications, pregnancy or breastfeeding, endocrine and gastrointestinal conditions, pancreatitis or gallbladder history, kidney function, and contraindications. Personal or family history of medullary thyroid carcinoma or MEN2 requires particular attention.
Nausea, vomiting, diarrhea, constipation, dehydration, kidney injury, gallbladder problems, and pancreatitis are important risks. Hypoglycemia can occur with insulin or certain diabetes medicines. Thyroid C-cell tumor warnings, pregnancy, severe gastrointestinal disease, and medication interactions require review. Tell your clinician about planned anesthesia or sedation. Seek urgent care for severe or persistent abdominal pain, serious allergic reactions, or other severe symptoms. Tirzepatide can affect oral hormonal contraceptive effectiveness; discuss contraception and any medication changes with the prescribing clinician.
A licensed clinician determines eligibility, whether a video or in-person visit is needed, the treatment plan, and appropriate follow-up under state law. Prescription approval is not guaranteed. Any prescribed medication must be dispensed by a licensed pharmacy. Follow only the prescriber’s and pharmacy’s instructions for the specific formulation and concentration.
Compounded medications are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Eligibility, appropriateness, and lawful availability require individual clinician and licensed-pharmacy review.